Clinical trials · New York
Metastatic Lung Cancer clinical trials in New York
We’re tracking 234 recruiting metastatic lung cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06472245RecruitingPhase 3
Cancer vaccine for lung cancer that stopped responding to immunotherapy
This trial tests a therapeutic cancer vaccine called OSE2101 for people with advanced non-small cell lung cancer whose tumors stopped responding to an immunotherapy drug. The vaccine is designed to help your immune system fight the cancer in a different way.
Babylon, New YorkAges 18 years+ - NCT05673148RecruitingPhase 2
Adding targeted tumor treatment to standard therapy for limited metastatic colorectal cancer
This trial tests whether adding a precise, targeted treatment to destroy remaining cancer spots (called total ablative therapy) after initial chemotherapy can improve outcomes for people with limited metastatic colorectal cancer. It aims to see if this extra treatment is safe and effective.
Brooklyn, New YorkAges 18 years+ - NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
New York, New YorkAges 18 years+ - NCT07365995RecruitingPhase 3
New drug for advanced prostate cancer vs. standard chemo
This trial tests a new drug called BNT324 against the standard chemotherapy docetaxel for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the new treatment can help control the cancer better.
Albany, New YorkAges 18 years+ - NCT06533644RecruitingPhase 2
SYNC-T therapy study for advanced prostate cancer
This trial tests a new treatment called SYNC-T Therapy (SV-102) for men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The therapy is given directly into a tumor to help your immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT06561386RecruitingPhase 3
Testing a new drug combo for advanced lung cancer
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Hawthorne, New YorkAges 18 years+ - NCT07357597RecruitingPhase 4
Preventing mouth sores during breast or lung cancer treatment
This trial tests whether a steroid mouthwash can prevent mouth sores caused by the drug Datopotamab Deruxtecan (Dato-DXd). It is for people with certain types of advanced breast cancer or lung cancer who are about to start Dato-DXd for the first time.
East Syracuse, New YorkAges 18 years+ - NCT04977453RecruitingPhase 1/Phase 2
Study drug GI-101 alone or with immune or blood-pressure meds
This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT07100080RecruitingPhase 2/Phase 3
New drug vs chemotherapy for EGFR-mutated lung cancer
This trial tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy (platinum plus pemetrexed) for people with a specific type of lung cancer that has an EGFR mutation and has stopped responding to newer targeted pills.
Mineola, New YorkAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
New York, New YorkAges 18 years+ - NCT06452277RecruitingPhase 3
Testing sevabertinib for advanced HER2-mutated lung cancer
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
New Hyde Park, New YorkAges 18 years+ - NCT06345729RecruitingPhase 3
Combination drug therapy for advanced lung cancer
This trial tests a new pill (calderasib) combined with an immunotherapy drug (pembrolizumab) for people with a specific type of advanced non-small cell lung cancer. It aims to see if the combination can shrink tumors or slow their growth.
Albany, New YorkAges 18 years+ - NCT05099172RecruitingPhase 1/Phase 2
Targeted therapy for advanced lung cancer with EGFR or HER2 changes
This trial tests a new targeted drug for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2). The drug may slow cancer growth and help you live longer.
Buffalo, New YorkAges 18 years+ - NCT06799065RecruitingPhase 1/Phase 2
Oral drug for advanced solid tumors including ovarian cancer
This trial tests a new daily pill that targets a protein helping cancer cells divide. It may stop tumors from growing in people with advanced or metastatic cancer that has returned or stopped responding to standard treatments, including some types of ovarian, lung, and other solid tumors.
Long Island City, New YorkAges 18 years+ - NCT04686305RecruitingPhase 1
Test drug T-DXd plus immunotherapy, with or without chemotherapy for HER2+ lung cancer
This Phase 1 study tests the safety (and early effectiveness) of T-DXd combined with immunotherapy, sometimes also with chemotherapy, in people with advanced lung cancer that is HER2-positive. It may help if standard options have been limited or your tumor does not have certain genetic changes that already have targeted treatments.
Buffalo, New YorkAges 18 years+ - NCT06855771RecruitingPhase 2
Study of navlimetostat alone or with izalontamab for advanced lung cancer
This trial tests a new drug, navlimetostat, either by itself or combined with another drug, izalontamab, for people with advanced non-small cell lung cancer that has a specific genetic change (MTAP loss). The goal is to see if these treatments can help shrink tumors or slow cancer growth.
New York, New YorkAges 18 years+ - NCT06654037RecruitingPhase 1
Testing abemaciclib plus 5-FU for advanced colorectal cancer
This trial is testing whether adding a targeted drug called abemaciclib to the standard chemotherapy 5-FU can help people with a specific type of advanced colorectal cancer (MSS) that has stopped responding to other treatments. The goal is to see if this combination is safe and effective.
The Bronx, New YorkAges 18 years+ - NCT04696575RecruitingPhase 2
Lamivudine added to chemoimmunotherapy for extensive-stage lung cancer
This trial tests whether adding lamivudine to standard chemoimmunotherapy can improve outcomes for people with extensive-stage small cell lung cancer. It aims to see if this combination controls the cancer better than standard treatment alone.
Buffalo, New YorkAges 18 years+ - NCT07607678RecruitingPhase 1
Testing BI 3819026 Alone and With Ezabenlimab for Advanced Cancer
This early-stage study tests whether a new drug called BI 3819026, alone or combined with another drug called ezabenlimab, is safe and well-tolerated in people whose advanced solid tumors have stopped responding to standard treatments. The goal is to find the right dose and understand how the drugs work in your body.
New York, New YorkAges 18 years+ - NCT07701941RecruitingPhase 1/Phase 2
Combination treatment for advanced breast cancer
This trial tests two targeted drugs together for people with advanced breast cancer that is hormone receptor positive and has low levels of a protein called HER2. The goal is to see if this combination helps shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Lake Success, New YorkAges 18–99 - NCT03449238RecruitingPhase 1/Phase 2
Pembrolizumab with focused brain radiation for breast cancer brain spread
This trial studies whether pembrolizumab (an immune therapy medicine) plus stereotactic radiosurgery (focused radiation) can better control brain metastases from breast cancer. It may help shrink or slow growth of multiple brain spots with minimal treatment to surrounding tissue.
New York, New YorkAges 19–90 - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for cancers with a KRAS G12D mutation
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
New York, New YorkAges 18 years+
Metastatic Lung Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting metastatic lung cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 6 studies
- NYU Langone Health · 4 studies
- Weill Cornell Medicine · 4 studies
- Columbia University Irving Medical Center · 2 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 2 studies
- New York Oncology Hematology · 2 studies
- Research Site · 2 studies
- Roswell Park Comprehensive Cancer Center · 2 studies
What taking part in a metastatic lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Lung Cancer trials in other states
Common questions
- Are there metastatic lung cancer clinical trials in New York?
- Yes. We're currently tracking 234 recruiting metastatic lung cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic lung cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic lung cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.